Medical Science Liaison - Oncology, Lake Michigan Region
NateraFull Time
Junior (1 to 2 years)
Candidates must possess an advanced scientific or medical degree (PhD, PharmD, MD, MSN, BSN) and a fundamental understanding of molecular oncology and related patient management algorithms. Existing relationships with Key Opinion Leaders (KOLs) in oncology, working knowledge of genomic laboratory-developed testing (LDT), familiarity with CLIA-88’, CAP, and Sunshine Act (2013) are required. Strong public speaking and interpersonal communication skills, along with the ability to educate and train, are essential. The role requires self-starting capabilities, an ownership mindset, the ability to work under tight deadlines, and willingness to travel up to 50%. A basic understanding of oncology is required, and basic understanding of molecular testing is strongly preferred. Preferred qualifications include 1+ years of MSL experience in diagnostics, biotech, or pharmaceutical industries.
The Medical Science Liaison will support commercial and educational objectives by acting as a regional expert on Tempus oncology assays and technologies. Responsibilities include promoting the exchange of clinical, scientific, and technical information with regional KOLs and other oncologists, and facilitating education for a broader healthcare provider community through presentations. This role involves providing scientific education for internal stakeholders, attending conferences to summarize key findings, and continuously updating internal teams on relevant medical and scientific knowledge while sharing market intelligence.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.